المؤلفون: Chao MP; Forty Seven, Inc., Menlo Park, CA, United States., Takimoto CH; Forty Seven, Inc., Menlo Park, CA, United States., Feng DD; Forty Seven, Inc., Menlo Park, CA, United States., McKenna K; Forty Seven, Inc., Menlo Park, CA, United States., Gip P; Forty Seven, Inc., Menlo Park, CA, United States., Liu J; Forty Seven, Inc., Menlo Park, CA, United States., Volkmer JP; Forty Seven, Inc., Menlo Park, CA, United States., Weissman IL; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, CA, United States., Majeti R; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Palo Alto, CA, United States.; Division of Hematology, Department of Medicine, Stanford, CA, United States.

المصدر: Frontiers in oncology [Front Oncol] 2020 Jan 22; Vol. 9, pp. 1380. Date of Electronic Publication: 2020 Jan 22 (Print Publication: 2019).

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: George GC; The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, TX, United States., Barata PC; Tulane University, New Orleans, LA, United States., Campbell A; Genentech, South San Francisco CA., Chen A; National Cancer Institute (NCI), Bethesda, MD, United States., Cortes JE; MD Anderson, Houston, TX, United States., Hyman DM; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Jones L, Karagiannis T; Genentech, Chicago, IL, United States., Klaar S; Swedish Medical Products Agency, Uppsala, Sweden., Le-Rademacher JG; Mayo Clinic, Rochester, MN, United States., LoRusso P; Yale University Cancer Center, New Haven, CT, United States., Mandrekar SJ; Mayo Clinic, Rochester, MN, United States., Merino DM; Friends of Cancer Research, Washington, DC, United States., Minasian LM; NCI, Bethesda, MD, United States., Mitchell SA; NCI, Rockville, MD, United States., Montez S; MD Anderson, Houston, TX, United States., O'Connor DJ; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom., Pettit S; Health and Environmental Sciences Institute, Washington DC, United States., Silk E, Sloan JA; Mayo Clinic, Rochester, MN, United States., Stewart M; NCI, Bethesda, MD, United States., Takimoto CH; Forty Seven, Inc., Menlo Park, CA, United States., Wong GY; Pfizer, New York NY, United States., Yap TA; MD Anderson, Houston, TX, United States., Cleeland CS; MD Anderson, Houston, TX, United States. Electronic address: ccleeland@mdanderson.org., Hong DS; MD Anderson, Houston, TX, United States. Electronic address: dshong@mdanderson.org.

المصدر: Cancer treatment reviews [Cancer Treat Rev] 2019 Jun; Vol. 76, pp. 33-40. Date of Electronic Publication: 2019 Apr 25.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7502030 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1967 (Electronic) Linking ISSN: 03057372 NLM ISO Abbreviation: Cancer Treat Rev Subsets: MEDLINE

مواضيع طبية MeSH: Adverse Drug Reaction Reporting Systems*, Antineoplastic Agents/*adverse effects, Clinical Trials, Phase III as Topic/methods ; Drug Development/methods ; Humans ; Randomized Controlled Trials as Topic/methods

المؤلفون: Sikic BI; 1 Stanford University School of Medicine, Stanford, CA., Lakhani N; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Patnaik A; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Shah SA; 1 Stanford University School of Medicine, Stanford, CA., Chandana SR; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Rasco D; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Colevas AD; 1 Stanford University School of Medicine, Stanford, CA., O'Rourke T; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Narayanan S; 1 Stanford University School of Medicine, Stanford, CA., Papadopoulos K; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Fisher GA; 1 Stanford University School of Medicine, Stanford, CA., Villalobos V; 4 University of Colorado Cancer Center, Aurora, CO., Prohaska SS; 1 Stanford University School of Medicine, Stanford, CA., Howard M; 1 Stanford University School of Medicine, Stanford, CA., Beeram M; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Chao MP; 5 Forty Seven, Menlo Park, CA., Agoram B; 5 Forty Seven, Menlo Park, CA., Chen JY; 5 Forty Seven, Menlo Park, CA., Huang J; 5 Forty Seven, Menlo Park, CA., Axt M; 5 Forty Seven, Menlo Park, CA., Liu J; 5 Forty Seven, Menlo Park, CA., Volkmer JP; 5 Forty Seven, Menlo Park, CA., Majeti R; 1 Stanford University School of Medicine, Stanford, CA.; 5 Forty Seven, Menlo Park, CA., Weissman IL; 1 Stanford University School of Medicine, Stanford, CA., Takimoto CH; 5 Forty Seven, Menlo Park, CA., Supan D; 1 Stanford University School of Medicine, Stanford, CA., Wakelee HA; 1 Stanford University School of Medicine, Stanford, CA., Aoki R; 1 Stanford University School of Medicine, Stanford, CA., Pegram MD; 1 Stanford University School of Medicine, Stanford, CA., Padda SK; 1 Stanford University School of Medicine, Stanford, CA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Apr 20; Vol. 37 (12), pp. 946-953. Date of Electronic Publication: 2019 Feb 27.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Lymphoma/*drug therapy , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/immunology ; Antineoplastic Agents, Immunological/pharmacokinetics ; Biopsy ; CD47 Antigen/immunology ; Cohort Studies ; Female ; Humans ; Lymphoma/immunology ; Lymphoma/metabolism ; Lymphoma/pathology ; Male ; Middle Aged ; Neoplasms/immunology ; Neoplasms/metabolism ; Neoplasms/pathology

المؤلفون: Sankhala K; Cedars-Sinai Medical Center, Beverly Hills, CA, USA., Takimoto CH; Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, TX, USA., Mita AC; Cedars-Sinai Medical Center, Los Angeles, CA, USA., Xiong H; The Center for Cancer and Blood Disorders/SCRI, Fort Worth, TX, USA., Rodón J; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mehrvarz Sarshekeh A; Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA., Burns K; Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, TX, USA., Iizuka K; Delta-Fly Pharma Inc., Tokushima, Japan., Kopetz S; Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. skopetz@mdanderson.org.

المصدر: Investigational new drugs [Invest New Drugs] 2019 Feb; Vol. 37 (1), pp. 76-86. Date of Electronic Publication: 2018 Apr 18.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacokinetics , Antineoplastic Agents/*pharmacology , Deoxycytidine/*analogs & derivatives , Isoflurophate/*chemistry , Neoplasms/*drug therapy, Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/pharmacokinetics ; Deoxycytidine/pharmacology ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Infusions, Intravenous ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/pathology ; Prognosis ; Tissue Distribution

المؤلفون: Advani R; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Flinn I; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Popplewell L; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Forero A; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Bartlett NL; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Ghosh N; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Kline J; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Roschewski M; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., LaCasce A; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Collins GP; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Tran T; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Lynn J; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Chen JY; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Volkmer JP; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Agoram B; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Huang J; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Majeti R; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Weissman IL; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Takimoto CH; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Chao MP; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.)., Smith SM; From Stanford University, Stanford (R.A., T.T., R.M., I.L.W.), City of Hope, Duarte (L.P.), and Forty Seven, Menlo Park (J.L., J.Y.C., J.-P.V., B.A., J.H., R.M., I.L.W., C.H.T., M.P.C.) - all in California; Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.F.); University of Alabama at Birmingham, Birmingham (A.F.); Washington University in St. Louis, St. Louis (N.L.B.); Levine Cancer Institute-Atrium Health, Charlotte, NC (N.G.); University of Chicago, Chicago (J.K., S.M.S.); National Cancer Institute, Rockville, MD (M.R.); Dana-Farber Cancer Institute, Boston (A.L.); and University of Oxford, Oxford, United Kingdom (G.P.C.).

المصدر: The New England journal of medicine [N Engl J Med] 2018 Nov 01; Vol. 379 (18), pp. 1711-1721.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , CD47 Antigen/*antagonists & inhibitors , Lymphoma, Follicular/*drug therapy , Lymphoma, Large B-Cell, Diffuse/*drug therapy , Macrophages/*physiology , Rituximab/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cell Cycle Checkpoints/drug effects ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Humans ; Macrophages/drug effects ; Male ; Middle Aged ; Phagocytosis/drug effects ; Rituximab/adverse effects

المؤلفون: Nikanjam M; University of California San Diego, 9500 Gilman Drive, MC 0657, La Jolla, CA, 92093-0657, USA., Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Mar; Vol. 75 (3), pp. 495-503. Date of Electronic Publication: 2015 Jan 04.

نوع المنشور: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Antineoplastic Agents/*pharmacokinetics , Organoplatinum Compounds/*pharmacokinetics, Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Area Under Curve ; Child ; Child, Preschool ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Creatinine/blood ; Dose-Response Relationship, Drug ; Female ; Humans ; Kidney Function Tests ; Male ; Middle Aged ; Monte Carlo Method ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Tissue Distribution ; Young Adult

المؤلفون: Saif MW; Authors' Affiliations: Tufts University School of Medicine, Boston, Massachusetts; Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas; Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; Memorial Sloan-Kettering Cancer Center, New York, New York; University of California San Diego; Biogen Indec, San Diego, California; University of Texas M.D. Anderson Cancer Center, Houston, Texas; and TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona., Takimoto C, Mita M, Banerji U, Lamanna N, Castro J, O'Brien S, Stogard C, Von Hoff D

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Jan 15; Vol. 20 (2), pp. 445-55. Date of Electronic Publication: 2013 Oct 04.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Adenine/*analogs & derivatives , Antineoplastic Agents/*pharmacology , Antineoplastic Agents/*therapeutic use , Neoplasms/*drug therapy , Neoplasms/*pathology , Pyridines/*pharmacology , Pyridines/*therapeutic use, Adenine/administration & dosage ; Adenine/adverse effects ; Adenine/pharmacology ; Adenine/therapeutic use ; Administration, Oral ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Biopsy ; Drug Administration Schedule ; Fluorodeoxyglucose F18 ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; HSP90 Heat-Shock Proteins/metabolism ; Humans ; Insulin-Like Growth Factor Binding Protein 2/blood ; Insulin-Like Growth Factor Binding Protein 2/metabolism ; Intracellular Space ; Leukocytes, Mononuclear/metabolism ; Neoplasm Staging ; Neoplasms/metabolism ; Positron-Emission Tomography ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Receptor, ErbB-2/blood

المؤلفون: Fetterly GJ; PK/PD Core Facility, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York., Aras U, Meholick PD, Takimoto C, Seetharam S, McIntosh T, de Bono JS, Sandhu SK, Tolcher A, Davis HM, Zhou H, Puchalski TA

المصدر: Journal of clinical pharmacology [J Clin Pharmacol] 2013 Oct; Vol. 53 (10), pp. 1020-7. Date of Electronic Publication: 2013 Jul 23.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Models, Biological*, Antibodies, Monoclonal/*pharmacokinetics , Antineoplastic Agents/*pharmacokinetics , Chemokine CCL2/*metabolism, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/blood ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing/administration & dosage ; Antibodies, Neutralizing/blood ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/blood ; Broadly Neutralizing Antibodies ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/metabolism ; Young Adult

المؤلفون: Kelly KR; Institute For Drug Development, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX, USA., Zollinger M, Lozac'h F, Tan E, Mita A, Waldmeier F, Urban P, Anand S, Wang Y, Swart P, Takimoto C, Mita M

المصدر: Investigational new drugs [Invest New Drugs] 2013 Jun; Vol. 31 (3), pp. 605-15. Date of Electronic Publication: 2012 Jul 18.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacokinetics , Epothilones/*pharmacokinetics , Neoplasms/*metabolism , Tubulin Modulators/*pharmacokinetics, Antineoplastic Agents/blood ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/urine ; Epothilones/blood ; Epothilones/therapeutic use ; Epothilones/urine ; Feces/chemistry ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/drug therapy ; Tubulin Modulators/blood ; Tubulin Modulators/therapeutic use ; Tubulin Modulators/urine

المؤلفون: Pienta KJ; University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 7308, Ann Arbor, MI, 48109, USA. kpienta@umich.edu, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, Dawkins F, de Bono JS

المصدر: Investigational new drugs [Invest New Drugs] 2013 Jun; Vol. 31 (3), pp. 760-8. Date of Electronic Publication: 2012 Aug 21.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antibodies, Neutralizing/*therapeutic use , Antineoplastic Agents/*therapeutic use , Chemokine CCL2/*immunology , Prostatic Neoplasms/*drug therapy, Aged ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing/pharmacology ; Antineoplastic Agents/pharmacology ; Broadly Neutralizing Antibodies ; Cell Count ; Chemokine CCL2/blood ; Endothelial Cells/cytology ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplastic Cells, Circulating ; Orchiectomy ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/pathology